Epstein-Barr virus nuclear antigen 2 induces FcRH5 expression through CBF1

Blood

Volumn 107, Issue 11, 2006, Pages 4433-4439

  Mohan, Joanne ^b   Dement Brown, Jessica ^b   Maier, Sabine ^b   Ise, Tomoko ^b   Kempkes, Bettina ^b   Tolnay, Mate ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS NUCLEAR ANTIGEN 2; FC RECEPTOR; FC RECEPTOR HOMOLOG 5; PROTEIN CBF1; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME 1Q; CONTROLLED STUDY; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SYNTHESIS;

EID: 33744460464     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-09-3815     Document Type: Article

References (59)

1. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004;4:757-768.
2. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B cells in vivo. Immunity. 1998;9:395-404.
3. Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol. 2003;24:584-588.
4. Grossman SR, Johannsen E, Tong X, Yalamanchili R, Kieff E. The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc Natl Acad Sci U S A. 1994;91:7568-7572.
5. Henkel T, Ling PD, Hayward SD, Peterson MG. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science. 1994;265:92-95.
6. Ling PD, Hsieh JJ, Ruf IK, Rawlins DR, Hayward SD. EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1. J Virol. 1994;68:5375-5383.
7. Laux G, Dugrillon F, Eckert C, et al. Identification and characterization of an Epstein-Barr virus nuclear antigen 2-responsive cis element in the bidirectional promoter region of latent membrane protein and terminal protein 2 genes. J Virol. 1994;68:6947-6958.
8. Johannsen E, Koh E, Mosialos G, et al. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. J Virol. 1995;69:253-262.
9. Fuentes-Panana EM, Peng R, Brewer G, Tan J, Ling PD. Regulation of the Epstein-Barr virus C promoter by AUF1 and the cyclic AMP/protein kinase A signaling pathway. J Virol. 2000;74:8166-8175.
10. Wang F, Gregory CD, Rowe M, et al. Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A. 1987;84:3452-3456.
11. Larcher C, Kempkes B, Kremmer E, et al. Expression of Epstein-Barr virus nuclear antigen-2 (EBNA2) induces CD21/CR2 on B and T cell lines and shedding of soluble CD21. Eur J Immunol. 1995;25:1713-1719.
12. Wang F, Gregory C, Sample C, et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol. 1990;64:2309-2318.
13. Cordier M, Calender A, Billaud M, et al. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J.Virol. 1990;64:1002-1013.
14. Kaiser C, Laux G, Eick D, et al. The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol. 1999;73:4481-4484.
15. Burgstahler R, Kempkes B, Steube K, Lipp M. Expression of the chemokine receptor BLR2/EBI1 is specifically transactivated by Epstein-Barr virus nuclear antigen 2. Biochem Biophys Res Commun. 1995;215:737-743.
16. Spender LC, Cornish GH, Sullivan A, Farrell PJ. Expression of transcription factor AML-2 (RUNX3, CBF(alpha)-3) is induced by Epstein-Barr virus EBNA-2 and correlates with the B-cell activation phenotype. J Virol. 2002;76:4919-4927.
17. Johansen LM, Deppmann CD, Erickson KD, et al. EBNA2 and activated Notch induce expression of BATF. J Virol. 2003;77:6029-6040.
18. Peng R, Moses SC, Tan J, Kremmer E, Ling PD. The Epstein-Barr virus EBNA-LP protein preferentially coactivates EBNA2-mediated stimulation of latent membrane proteins expressed from the viral divergent promoter. J Virol. 2005;79:4492-4505.
19. Maier S, Santak M, Mantik A, et al. A somatic knockout of CBF1 in a human B-cell line reveals that induction of CD21 and CCR7 by EBNA-2 is strictly CBF1 dependent and that downregulation of immunoglobulin M is partially CBF1 independent. J Virol. 2005;79:8784-8792.
20. Spender LC, Cornish GH, Rowland B, Kempkes B, Farrell PJ. Direct and indirect regulation of cytokine and cell cycle proteins by EBNA-2 during Epstein-Barr virus infection. J Virol. 2001;75:3537-3546.
21. Pages F, Galon J, Karaschuk G, et al. Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells. Blood. 2005;105:1632-1639.
22. Jochner N, Eick D, Zimber-Strobl U, et al. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells. EMBO J. 1996;15:375-382.
23. Hsieh JJ, Nofziger DE, Weinmaster G, Hayward SD. Epstein-Barr virus immortalization: Notch2 interacts with CBF1 and blocks differentiation. J Virol. 1997;71:1938-1945.
24. Hsieh JJ, Hayward SD. Masking of the CBF1/RBPJ kappa transcriptional repression domain by Epstein-Barr virus EBNA2. Science. 1995;268:560-563.
25. Hsieh JJ, Henkel T, Salmon P, et al. Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2. Mol Cell Biol. 1996;16:952-959.
26. Hubmann R, Schwarzmeier JD, Shehata M, et al. Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. Blood. 2002;99:3742-3747.
27. Gordadze AV, Peng R, Tan J, et al. Notch1IC partially replaces EBNA2 function in B cells immortalized by Epstein-Barr virus. J Virol. 2001;75:5899-5912.
28. Hatzivassiliou G, Miller I, Takizawa J, et al. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity. 2001;14:277-289.
29. Davis RS, Wang YH, Kubagawa H, Cooper MD. Identification of a family of Fc receptor homologs with preferential B cell expression. Proc Natl Acad Sci U S A. 2001;98:9772-9777.
30. Nakayama Y, Weissman SM, Bothwell AL. BXMAS1 identifies a cluster of homologous genes differentially expressed in B cells. Biochem Biophys Res Commun. 2001;285:830-837.
31. Davis RS, Stephan RP, Chen CC, Dennis G Jr, Cooper MD. Differential B cell expression of mouse Fc receptor homologs. Int Immunol. 2004;16:1343-1353.
32. Davis RS, Dennis G Jr, Odom MR, et al. Fc receptor homologs: newest members of a remarkably diverse Fc receptor gene family. Immunol Rev. 2002;190:123-136.
33. Davis RS, Ehrhardt GR, Leu CM, Hirano M, Cooper MD. An extended family of Fc receptor relatives. Eur J Immunol. 2005;35:674-680.
34. Ehrhardt GR, Davis RS, Hsu JT, et al. The inhibitory potential of Fc receptor homolog 4 on memory B cells. Proc Natl Acad Sci U S A. 2003;100:13489-13494.
35. Leu CM, Davis RS, Gartland LA, Fine WD, Cooper MD. FcRH1: an activation coreceptor on human B cells. Blood. 2005;105:1121-1126.
36. Miller I, Hatzivassiliou G, Cattoretti G, Mendelsohn C, Ia-Favera R. IRTAs: a new family of immunoglobulinlike receptors differentially expressed in B cells. Blood. 2002;99:2662-2669.
37. Ise T, Maeda H, Santora K, et al. Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies. Clin Cancer Res. 2005;11:87-96.
38. Kempkes B, Spitkovsky D, Jansen-Durr P, et al. B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J. 1995;14:88-96.
39. Klein G, Lindahl T, Jondal M, et al. Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas. Proc Natl Acad Sci U S A. 1974;71:3283-3286.
40. Menezes J, Leibold W, Klein G, Clements G. Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine. 1975;22:276-284.
41. Sobol H, Benziane A, Kerangueven F, et al. Genome-wide search for loss of heterozygosity in Burkitt lymphoma cell lines. Genes Chromosomes Cancer. 2002;33:217-224.
42. Engler-Blum G, Meier M, Frank J, Muller GA. Reduction of background problems in nonradioactive northern and Southern blot analyses enables higher sensitivity than 32P-based hybridizations. Anal Biochem. 1993;210:235-244.
43. Tolnay M, Vereshchagina LA, Tsokos GC. NF-kappaB regulates the expression of the human complement receptor 2 gene. J Immunol. 2002;169:6236-6243.
44. Orlando V, Strutt H, Paro R. Analysis of chromatin structure by in vivo formaldehyde cross-linking. Methods. 1997;11:205-214.
45. Quandt K, Frech K, Karas H, Wingender E, Werner T. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res. 1995;23:4878-4884.
46. Greenbaum D, Colangelo C, Williams K, Gerstein M. Comparing protein abundance and mRNA expression levels on a genomic scale [review]. Genome Biol. 2003;4:117.
47. Cordier-Bussat M, Billaud M, Calender A, Lenoir GM. Epstein-Barr virus (EBV) nuclear-antigen-2-induced up-regulation of CD21 and CD23 molecules is dependent on a permissive cellular context. Int J Cancer. 1993;53:153-160.
48. Caldwell RG, Wilson JB, Anderson SJ, Long-necker R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity. 1998;9:405-411.
49. Hayward SD. Viral interactions with the Notch pathway. Semin Cancer Biol. 2004;14:387-396.
50. Alazard N, Gruffat H, Hiriart E, Sergeant A, Manet E. Differential hyperacetylation of histones H3 and H4 upon promoter-specific recruitment of EBNA2 in Epstein-Barr virus chromatin. J Virol. 2003;77:8166-8172.
51. Tolnay M, Lambris JD, Tsokos GC. Transcriptional regulation of the complement receptor 2 gene: role of a heterogeneous nuclear ribonucleoprotein. J Immunol. 1997;159:5492-5501.
52. Tanigaki K, Han H, Yamamoto N, et al. Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells. Nat Immunol. 2002;3:443-450.
53. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306:269-271.
54. Liang Y, Chang J, Lynch SJ, Lukac DM, Ganem D. The lytic switch protein of KSHV activates gene expression via functional interaction with RBP-Jkappa (CSL), the target of the Notch signaling pathway. Genes Dev. 2002;16:1977-1989.
55. Ansieau S, Strobl LJ, Leutz A. Activation of the Notch-regulated transcription factor CBF1/RBP-Jkappa through the 13SE1A oncoprotein. Genes Dev. 2001;15:380-385.
56. Chang H, Gwack Y, Kingston D, et al. Activation of CD21 and CD23 gene expression by Kaposi's sarcoma-associated herpesvirus RTA. J Virol. 2005;79:4651-4663.
57. Wolf BC, Martin AW, Neiman RS, et al. The detection of Epstein-Barr virus in hairy cell leukemia cells by in situ hybridization. Am J Pathol. 1990;136:717-723.
58. Nordstrom M, Hardell L, Linde A, Schloss L, Nasman A. Elevated antibody levels to Epstein-Barr virus antigens in patients with hairy cell leukemia compared to controls in relation to exposure to pesticides, organic solvents, animals, and exhausts. Oncol Res. 1999;11:539-544.
59. Chang KL, Chen YY, Weiss LM. Lack of evidence of Epstein-Barr virus in hairy cell leukemia and monocytoid B-cell lymphoma. Hum Pathol. 1993;24:58-61.